Fig. 1: Outcomes associated with Bruton tyrosine kinase inhibitor (BTKi) treatment and next line therapy. | Blood Cancer Journal

Fig. 1: Outcomes associated with Bruton tyrosine kinase inhibitor (BTKi) treatment and next line therapy.

From: Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy

Fig. 1

Progression-free survival (PFS) from BTKi initiation (A). Reasons for BTKi discontinuation (B). Overall survival (OS) from BTKi initiation (C). OS stratified by treatment status (D). OS from BTKi discontinuation date (E). Next line therapy stratified by first BTKi agent (F). Response rate associated with next line therapy (G). Overall survival (OS) and progression-free survival (PFS) analyses based on next line of treatment after BTKi discontinuation (H, I). AE adverse event, A-Fib atrial fibrillation, CR complete response, LBCL large B cell lymphoma, MR minor response, ORR overall response rate, PD progressive disease, PR partial response, Pt patient, RR relapsed/refractory, SD stable disease, T-Naïve treatment naïve, VGPR very good partial response, WM Waldenström macroglobulinemia.

Back to article page